Acquired hypothalamic obesity

Acquired HO

Actor portrayal
Girl sitting and holding a book in soccer-themed bedroom. Actor portrayal.

Acquired hypothalamic obesity is a unique form of obesity caused by injury to the hypothalamus1-4

Acquired hypothalamic obesity (HO) is characterized by accelerated and sustained weight gain.1–4
Healthy Hypothalamus5,6

The hypothalamus plays a key role in many diverse functions, including regulating:

Satiety and hunger

Energy expenditure

Body weight

Right arrow
Injury to the hypothalamus graphic

Patients with injury to the hypothalamus experience a variety of health concerns, one of which is acquired HO.5,6

Right arrow
Acquired Hypothalamic Obesity5,6

Unlike general obesity, acquired HO is characterized by distinct factors that can contribute to weight gain:

Hyperphagia

Decreased energy expenditure

Accelerated, sustained
weight gain

Differences in type, location, and extent of hypothalamic injury may result in variable time to onset and progression of weight gain.5,7

While HO can be congenital or acquired, more than 80% of cases are acquired.8

Questions about acquired hypothalamic obesity?

Causes of acquired HO

Faded head image
Known Common Causes8:
  • Brain tumors, including craniopharyngioma, astrocytoma, and macroadenoma of the pituitary
  • Brain tumor treatment, including surgical resection and radiotherapy
Other Causes8:
  • Traumatic brain injury
  • Stroke
  • Disorders that cause inflammation to the hypothalamus

Know who is at risk—acquired HO occurs in up to 75% of patients with craniopharyngioma following treatment.9

Mechanism of disease

Acquired HO has an underlying pathophysiology that distinguishes it from general obesity.1,2,4

The melanocortin-4 receptor (MC4R) pathway regulates hunger, satiety, and energy balance.10–12
Alpha-melanocyte-stimulating hormone is produced in the hypothalamus and activates MC4 receptors expressed across the central nervous system. The hormone is produced by POMC neurons and binds to MC4 receptors to activate the MC4R pathway, which controls hunger, satiety, and energy expenditure that results in regulated body weight.
Injury to the hypothalamus can disrupt MC4R pathway signaling, ultimately
leading to accelerated and sustained weight gain.13,14
Hypothalamic injury can affect production of alphamelanocyte- stimulating hormone, and this decreased production leads to decreased MC4R activation. This then impairs MC4R pathway signaling, which may lead to hyperphagia and decreased energy expenditure that results in accelerated and sustained weight gain.

POMC=Proopiomelanocortin

References
  1. Abuzzahab MJ, Roth CL, Shoemaker AH. Hypothalamic obesity: prologue and promise. Horm Res Paediatr. 2019;91(2):128-136. doi:10.1159/000496564
  2. Roth CL. Hypothalamic obesity in patients with craniopharyngioma: profound changes of several weight regulatory circuits. Front Endocrinol (Lausanne). 2011;2:49. doi:10.3389/fendo.2011.00049
  3. Roth CL, Enriori PJ, Gebhardt U, et al. Changes of peripheral alpha-melanocyte-stimulating hormone in childhood obesity. Metabolism. 2010;59(2):186-194. doi:10.1016/j.metabol.2009.06.031
  4. Roth CL, Gebhardt U, Müller HL. Appetite-regulating hormone changes in patients with craniopharyngioma. Obesity (Silver Spring). 2011;19(1):36-42. doi:10.1038/oby.2010.80
  5. Roth CL. Hypothalamic obesity in craniopharyngioma patients: disturbed energy homeostasis related to extent of hypothalamic damage and its implication for obesity intervention. J Clin Med. 2015;4(9):1774-1797. Published 2015 Sep 9. doi:10.3390/jcm4091774
  6. van Santen HM, van Schaik J, van Roessel IMAA, Beckhaus J, Boekhoff S, Müller HL. Diagnostic criteria for the hypothalamic syndrome in childhood. Eur J Endocrinol. 2023;188(2):lvad009. doi:10.1093/ejendo/lvad009
  7. Müller HL. Craniopharyngioma and hypothalamic injury: latest insights into consequent eating disorders and obesity. Curr Opin Endocrinol Diabetes Obes. 2016;23(1):81-89. doi:10.1097/MED.0000000000000214
  8. Rose SR, Horne VE, Bingham N, Jenkins T, Black J, Inge T. Hypothalamic obesity: 4 years of the International Registry of Hypothalamic Obesity Disorders. Obesity (Silver Spring). 2018;26(11):1727-1732. doi:10.1002/oby.22315
  9. Lustig RH. Hypothalamic obesity after craniopharyngioma: mechanisms, diagnosis, and treatment. Front Endocrinol (Lausanne). 2011 Nov 3;2:60. doi:10.3389/fendo.2011.00060
  10. Timper K, Brüning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech. 2017;10(6):679-689. doi:10.1242/dmm.026609
  11. Vlaardingerbroek H, van den Akker ELT, Hokken-Koelega ACS. Appetite- and weight-inducing and -inhibiting neuroendocrine factors in Prader-Willi syndrome, Bardet-Biedl syndrome and craniopharyngioma versus anorexia nervosa. Endocr Connect. 2021;10:R175-R188. doi:10.1530/EC-21-0111
  12. Haliloglu B, Bereket A. Hypothalamic obesity in children: pathophysiology to clinical management. J Pediatr Endocrinol Metab. 2015;28(5-6):503-513. doi:10.1515/jpem-2014-0512
  13. Kayadjanian N, Hsu EA, Wood AM, Carson DS. Caregiver burden and its relationship to health-related quality of life in craniopharyngioma survivors. J Clin Endocrinol Metab. 2023;109(1):e76-e87. doi:10.1210/clinem/dgad488
  14. Craven M, Crowley JH, Chiang L, et al. A survey of patient-relevant outcomes in pediatric craniopharyngioma: focus on hypothalamic obesity. Front Endocrinol (Lausanne). 2022;13:876770. Published May 9, 2022. doi:10.3389/fendo.2022.876770